Land­mark CRISPR ap­proval; Why don't in­vestors like Verve’s base edit­ing da­ta?; Janet Wood­cock to re­tire; Late Fri­day IPO fil­ing; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

This week, we show­case End­points’ on-the-ground cov­er­age with dis­patch­es from the AHA meet­ing in Philadel­phia and the Jef­feries con­fer­ence in Lon­don. But don’t miss the string of new ap­provals, deals, fi­nanc­ing and de­par­tures, ei­ther.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER